People: Hyperion Therapeutics Inc (HPTX.W)
HPTX.W on CBOE When Trading NASDAQ Global Select Market
22.32USD
17 May 2013
22.32USD
17 May 2013
Price Change (% chg)
$-0.01 (-0.04%)
$-0.01 (-0.04%)
Prev Close
$22.33
$22.33
Open
$22.61
$22.61
Day's High
$22.68
$22.68
Day's Low
$22.32
$22.32
Volume
1,000
1,000
Avg. Vol
121
121
52-wk High
$25.89
$25.89
52-wk Low
$10.19
$10.19
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
James Healy |
47 | 2009 | Chairman of the Board |
Donald Santel |
52 | President, Chief Executive Officer, Director | |
Jeffrey Farrow |
51 | Chief Financial Officer, Secretary | |
Klara Dickinson |
45 | 2007 | Senior Vice President - Regulatory Affairs and Compliance |
Christine Nash |
40 | 2012 | Senior Vice President, Chief Commercial Officer |
Bruce Scharschmidt |
66 | 2008 | Senior Vice President, Chief Medical Officer |
David Gryska |
57 | Lead Independent Director | |
Jake Nunn |
42 | 2009 | Director |
Bijan Salehizadeh |
39 | 2007 | Director |
Bo Jesper Hansen |
54 | 2011 | Independent Director |
Daniel Welch |
55 | 2012 | Independent Director |
Lota Zoth |
53 | 2008 | Independent Director |
Biographies
| Name | Description |
|---|---|
James Healy |
Dr. James I. Healy, M.D., Ph.D., is Chairman of the Board of Hyperion Therapeutics, Inc. He has been a member of the board of directors since 2006 and Chairman of the board of directors since July 2009. Dr. Healy has been a General Partner of Sofinnova Ventures, a venture capital firm, since June 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories) and ISTA Pharmaceuticals, Inc. Dr. Healy is currently on the board of directors of Amarin Corporation plc, Anthera Pharmaceuticals, Inc., InterMune, Inc., and several private companies. Previously, he served as a board member of CoTherix, Inc. and Movetis NV and several private companies. Dr. Healy holds an M.D. and a Ph.D. in Immunology from the Stanford School of Medicine and holds a B.A. in molecular biology and a B.A. in Scandinavian Studies from the University of California at Berkeley. Dr. Healy’s experience in the pharmaceutical industries and investing in life sciences companies, as well as his medical and scientific background, provide him with the qualifications and skills to serve as a director. |
Donald Santel |
Mr. Donald J. Santel is President, Chief Executive Officer, Director of Hyperion Therapeutics, Inc. He has served as Chief Executive Officer since June 2008. Mr. Santel has been a member of the board of directors since March 2007. Previously, Mr. Santel was a member of the board of directors and the Chief Executive Officer of CoTherix, Inc., a biopharmaceutical company he co-founded in 2000 and brought public in 2004, where he was responsible for the oversight of all aspects of the business and led the sale of the company to Actelion in January 2007. Prior to joining CoTherix, Mr. Santel was employed by or consultant to several medical device companies, including Reflow, Inc., Cardiac Pathways Corporation and Medtronic, Inc. Mr. Santel previously served on the board of directors and the audit and compensation committees of Anthera Pharmaceuticals, Inc. and as a director of ChemGenex Pharmaceuticals, Inc. Mr. Santel holds an M.S. in electrical engineering from the University of Minnesota and a B.S.E. in biomedical engineering from Purdue University. |
Jeffrey Farrow |
Mr. Jeffrey S. Farrow is Chief Financial Officer, Secretary of Hyperion Therapeutics, Inc. He has served as Chief Financial Officer since July 2010 and served as Vice President, Finance from February 2010 to June 2010. From May 2008 to December 2009, Mr. Farrow was Vice President, Finance at Evotec AG, a drug discovery and development company, where Mr. Farrow was responsible for Evotec’s corporate treasury function and compliance with the Sarbanes Oxley Act, as well as overseeing the finance and general & administrative functions of the company’s Renovis subsidiary. From January 2004 to May 2008, Mr. Farrow held various positions, with the most recent being Vice President, Finance and Chief Accounting Officer, at Renovis, Inc., a drug discovery and development company, which was acquired by Evotec AG in May 2008. While at Renovis Mr. Farrow was a key member of the management team responsible for the merger with Evotec, as well as Renovis’ initial public offering and secondary offering. Previously, Mr. Farrow held various positions over his seven years in the audit practice of KPMG LLP and was most recently a Senior Manager. Mr. Farrow holds a B.A. in Business Administration with a concentration in Corporate Finance from California State University at Fullerton. |
Klara Dickinson |
Ms. Klara A. Dickinson is Senior Vice President - Regulatory Affairs and Compliance of Hyperion Therapeutics, Inc. Previously, Ms. Dickinson spent three years with CoTherix, Inc. and was most recently Vice President, Regulatory Affairs and Healthcare Compliance Officer from January 2004 to January 2007. In that role, Ms. Dickinson led the filing of the NDA and label negotiations for the company’s initial product, Ventavis® (iloprost) Inhalation Solution. Prior to CoTherix, Inc., Ms. Dickinson held various positions at biopharmaceutical companies Scios, Inc. and DEY Laboratories, a subsidiary of Mylan, Inc. Ms. Dickinson holds a B.S. in Biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board. |
Christine Nash |
Ms. Christine A. Nash is Senior Vice President, Chief Commercial Officer of Hyperion Therapeutics, Inc. From August 2008 until May 2012 she served as Vice President, Strategic Marketing and Corporate Business Development and she joined the Company in August 2007 as Senior Director, Marketing. From October 2004 to February 2007, Ms. Nash held various positions at CoTherix, Inc., including most recently as Director of Marketing. As Director of Marketing, Ms. Nash led all marketing and product support aspects for the launch of the company’s initial product, Ventavis® (iloprost) Inhalation Solution. Ms. Nash’s previous experience includes business development and product planning and management roles with Genesoft Pharmaceuticals Inc., Oncology Therapeutics Network, Eli Lilly and Company, and Imana, Inc. Ms. Nash holds an M.B.A and a B.A. with Honors in Public Policy, both from Stanford University. |
Bruce Scharschmidt |
Dr. Bruce F. Scharschmidt, M.D., is Senior Vice President, Chief Medical Officer of Hyperion Therapeutics, Inc. From April 2006 to April 2008, Dr. Scharschmidt served as Vice President of Scientific Affairs for NOVARTIS Vaccines, a division of NOVARTIS, a healthcare products company, where Dr. Scharschmidt was responsible for developing the clinical strategy for early-stage vaccines. From August 1996 to April 2006, Dr. Scharschmidt held senior positions at Chiron Corporation, including VP and head of clinical development for vaccines and therapeutics and, most recently, as Vice President of Scientific Affairs in the Corporate Group, where he was involved in the strategic direction and management of key research and development programs including vaccines, therapeutics and blood testing. Before joining Chiron, Dr. Scharschmidt was Chief of Gastroenterology and Professor of Medicine at the University of California San Francisco. Dr. Scharschmidt received both his M.D. and undergraduate degree from Northwestern University as part of a six-year Honors Program in Medical Education. Dr. Scharschmidt completed his training in Internal Medicine and Gastroenterology at the University of California, San Francisco. |
David Gryska |
Mr. David W. Gryska is Lead Independent Director of Hyperion Therapeutics, Inc. He has been a member of the board of directors since November 2010. Since May 11, 2012, Mr. Gryska has served as Chief Operating Officer of Myrexis Inc., a biotechnology company. From December 2006 to October 2010, Mr. Gryska served as Senior Vice President and Chief Financial Officer of Celgene Corporation, a biopharmaceutical company. From October 2004 to December 2006, he was a principal at Strategic Consulting Group, where he provided strategic consulting to early-stage biotechnology companies. Prior to that time, Mr. Gryska held positions at Scios, Inc. and Cardiac Pathways Corporation and served as a partner at Ernst & Young LLP. Mr. Gryska currently serves as a member of the board of directors of Seattle Genetics, Inc. Mr. Gryska holds an M.B.A. from Golden Gate University and a B.A. in accounting and finance from Loyola University. Mr. Gryska is also a Certified Public Accountant. |
Jake Nunn |
Mr. Jake R. Nunn is Director of Hyperion Therapeutics, Inc. Mr. Nunn joined New Enterprise Associates, Inc., a venture capital firm, in 2006 as a Partner, where he focuses on later-stage specialty pharmaceuticals, biotechnology and medical device investments. From January 2001 to June 2006, Mr. Nunn served as a Partner and an analyst for the MPM BioEquities Fund, a public life sciences fund at MPM Capital, L.P., a private equity firm, where he specialized in life sciences investing. Previously, Mr. Nunn was a healthcare research analyst and portfolio manager at Franklin Templeton Investments and an investment banker with Alex, Brown & Sons. Mr. Nunn is currently on the boards of directors at Transcept Pharmaceuticals, Inc. and three private companies. Mr. Nunn received an M.B.A. from the Stanford University Graduate School of Business and an A.B. in Economics from Dartmouth College. Mr. Nunn holds the Chartered Financial Analyst designation, and is a member of the CFA Society of San Francisco. |
Bijan Salehizadeh |
Dr. Bijan Salehizadeh, M.D., is Director of Hyperion Therapeutics, Inc. Dr. Salehizadeh currently serves as co-founder and Managing Director at NaviMed Capital Advisors LLC, a private investment firm focused on growth venture capital healthcare investments. Dr. Salehizadeh also serves as an advisor to Highland Capital Partners LLC, a venture capital firm. From September 2004 to August 2011, Dr. Salehizadeh was an investment professional at Highland Capital Partners, where he most recently served as General Partner. Dr. Salehizadeh focused on healthcare investments, primarily in medical products, healthcare services, and biopharmaceutical companies. Prior to this, Dr. Salehizadeh served in various positions at Medtronic and HealthCentral. Dr. Salehizadeh currently serves on the board of directors of several private healthcare companies. Dr. Salehizadeh received an M.D. and an M.S. in Health Policy from Columbia University, an M.B.A. from Harvard Business School and an A.B. in Molecular Biology from Princeton University. |
Bo Jesper Hansen |
Dr. Bo Jesper Hansen, M.D., Ph.D., is Independent Director of Hyperion Therapeutics, Inc. Since January 2010, Dr. Hansen has served as chairman of the board of Swedish Orphan Biovitrum AB, a Swedish specialty pharmaceutical company focusing on rare diseases with unmet medical needs. Previously, Dr. Hansen held various positions in Swedish Orphan International AB from 1993 and was President and Chief Executive Officer of Swedish Orphan International Group of Companies from 1998 until the merger with Biovitrum in 2010. Prior to joining Swedish Orphan International AB, Dr. Hansen worked as a medical advisor for several of the pharmaceutical companies throughout the world, including Synthélabo, Pfizer, Inc., Pharmacia Corporation and Yamanouchi Pharmaceutical Co. Ltd. Dr. Hansen also founded the company Scandinavian Medical Research. Dr. Hansen is the chairman of the board of directors of Topotarget A/S and is a member of the boards of directors of two private companies. Dr. Hansen received an M.D. and a Ph.D. from the University of Copenhagen. |
Daniel Welch |
Mr. Daniel G. Welch is Independent Director of Hyperion Therapeutics, Inc. Mr. Welch has served as Chairman of the board of directors at InterMune, Inc., a biotechnology company, since May 2008 and as President, Chief Executive Officer and a member of the board of directors of InterMune since September 2003. Prior to that time, Mr. Welch served as a consultant to Warburg Pincus LLC, a global private equity investment firm, as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc. and as President of the pharmaceutical division of Elan Corporation, PLC. Mr. Welch has served on the board of directors of Seattle Genetics, a biotechnology company, since 2007, and also serves on the board of directors of a private company. Mr. Welch holds a B.S. from the University of Miami and an M.B.A. from the University of North Carolina. |
Lota Zoth |
Ms. Lota S. Zoth is Independent Director of Hyperion Therapeutics, Inc. Ms. Zoth served as Senior Vice President and Chief Financial Officer of MedImmune, Inc. from April 2004 to July 2007 and also served as its Controller and Principal Accounting Officer. Prior to joining MedImmune in 2002, Ms. Zoth served as Senior Vice President, Corporate Controller and Principal Accounting Officer at PSINet Inc., Vice President, Corporate Controller and Chief Accounting Officer at Sodexho Marriott Services, Inc., Marriott International and PepsiCo, Inc. Ms. Zoth also served as an auditor at Ernst & Young, LLP and is a Certified Public Accountant. Ms. Zoth is a member of the boards of directors of Orexigen Therapeutics, Inc. and two private companies. Ms. Zoth received a B.B.A. in accounting from Texas Tech University. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
James Healy |
-- |
Donald Santel |
1,641,020 |
Jeffrey Farrow |
857,742 |
Klara Dickinson |
776,254 |
Christine Nash |
783,640 |
Bruce Scharschmidt |
971,883 |
David Gryska |
-- |
Jake Nunn |
-- |
Bijan Salehizadeh |
-- |
Bo Jesper Hansen |
-- |
Daniel Welch |
-- |
Lota Zoth |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
James Healy |
0 | 0 |
Donald Santel |
0 | 0 |
Jeffrey Farrow |
0 | 0 |
Klara Dickinson |
0 | 0 |
Christine Nash |
0 | 0 |
Bruce Scharschmidt |
54,227 | 0 |
David Gryska |
0 | 0 |
Jake Nunn |
0 | 0 |
Bijan Salehizadeh |
0 | 0 |
Bo Jesper Hansen |
0 | 0 |
Daniel Welch |
0 | 0 |
Lota Zoth |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
SCHARSCHMIDT BRUCE FREDERICK |
10,384 | $4.08 |
SCHARSCHMIDT BRUCE FREDERICK |
43,843 | $1.28 |
HIGHLAND MANAGEMENT PARTNERS VII L L C |
132,601 | $0.00 |
BASKETT FOREST |
177,481 | $0.00 |
PANORAMA CAPITAL L P |
1,125 | $0.00 |
NASH CHRISTINE A |
97 | $0.00 |
SANDELL SCOTT D |
611,185 | $0.00 |
DRANT RYAN D |
125,291 | $0.00 |
BAY CITY CAPITAL L L C |
477,893 | $10.00 |
BAY CITY CAPITAL L L C |
2,741 | $10.00 |
SANDELL SCOTT D |
177,481 | $0.00 |
SANDELL SCOTT D |
125,291 | $0.00 |
BARRIS PETER J |
500,000 | $10.00 |
AGGARWAL GAURAV |
5,000 | $10.00 |
HIGHLAND MANAGEMENT PARTNERS VII L L C |
425,958 | $0.00 |
KRAMLICH C RICHARD |
611,185 | $0.00 |
KERINS PATRICK J |
898,808 | $0.00 |
HIGHLAND MANAGEMENT PARTNERS VII L L C |
103,218 | $0.00 |
BASKETT FOREST |
611,185 | $0.00 |
KRAMLICH C RICHARD |
180,459 | $0.00 |
NEWHALL CHARLES W III |
2,043 | $0.00 |
SANDELL SCOTT D |
2,043 | $0.00 |
BAY CITY CAPITAL L L C |
2,787 | $10.00 |
HIGHLAND MANAGEMENT PARTNERS VII L L C |
375,755 | $0.00 |
HIGHLAND MANAGEMENT PARTNERS VII L L C |
262 | $0.00 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
